The contract provides that the four EU States can order up to 400 million doses of in-development vaccine, such as the company, as well as the German and the Italian government said on Saturday.
The Quartet, a rise in the global race for resources against the Coronavirus, which is brought according to the Johns Hopkins University with more than 426’000 deaths worldwide in connection. “Many countries in the world have already secured the vaccines Europe, not yet,” stressed the German Minister of health, Jens Spahn.
GAVI has advantages
The four States have joined an Alliance together, said the German health Ministry and the Italian health Minister Roberto Speranza. You were with several companies in the conversation, the promising vaccines researched, it was said.
This vaccines very quickly after a potential approval in this or in the next year, a large number are available, would have to production capacity to be secured in a contract.
In the contract, it goes up to 400 million doses of the vaccine, the AstraZeneca developed together with the University of Oxford. The first doses should be available by the end of the year, announced Speranza on Facebook.
– construction of a factory in Europe
“The agreement ensures that hundreds of millions of Europeans have access to the vaccine at the University of Oxford, if he is allowed,” said AstraZeneca CEO Pascal Soriot. You’ll quickly build up a production in Europe.
The company has closed according to their own information of a similar agreement with the UK, the USA and the international vaccine Alliance Gavi. With India there is a license agreement for the production of a Billion doses of the vaccine, especially for developing and emerging countries.
Currently, you could produce two trillion doses. Pascal also announced that China, Brazil, Japan and Russia have also expressed interest in an agreement for the provision of a possible vaccine.
Feverish search runs hot
the World is researched in several projects feverishly on vaccines and drugs against the Coronavirus. The University of Oxford announced in may that it would enter into the second Phase of testing, with approximately 10’000 subjects. AstraZeneca pointed out that the success of the vaccine-development was not backed up.
As the largest carrier of hope among the potential Corona-drugs of the Mediterranean Remdesivir of the US company Gilead is currently. The biotechnology group has already received US FDA approval for the use of Remdesivir in case of emergencies. For the EU, Gilead has requested this. Switzerland continues to fight alone. (SDA/uro)
Lonza on Board in support of the U.S.-Corona-vaccine-company
every Day there are new reports about promising Corona vaccines. At the world health organization (WHO), currently nearly 80 Corona vaccine developers recorded. Although feverishly research, experts at the earliest until the beginning of 2021, with the first broadly applicable vaccine.
in March, with Tests on humans, the US-based company Moderna launched. In the same boat: the Swiss pharmaceutical supplier Lonza. This was announced last week an agreement with Moderna for the production of the Corona vaccine. In July, the U.S. subsidiary of Lonza will manufacture the first batches. The two companies plan to jointly produce up to one billion cans. The Lonza drives on the stock exchange in the amount. The share price rose on Monday – in an otherwise declining trade. However, as yet no vaccine that has emerged on the genbasierten method of Moderna has received the approval.
the British are ahead in the race
As very promising is the vaccine a research team from Oxford (UK). He resigned two weeks ago in the sensitive clinical test phase. The British use attenuated harmless viruses, which are disguised as a Coronavirus, so-called vectors, in the body trigger an immune reaction. The same method uses Janssen Vaccines at the time of his Corona-vaccine. The method has already proved its worth in the case of Ebola, and HIV. The U.S. government announced in April to invest almost half a billion dollars in the development and production of the Corona vaccines, Janssen as well as Moderna.
Already been clinical Tests and Chinese research groups. Starting in June, will also launch the Team of Martin Bachmann (52) of the University of Bern and other universities, as well as the company Saiba with clinical trial. Green light for human testing has received two weeks ago, in addition, the German company Biontech, in cooperation with Pfizer.
